冠状动脉疾病中的表观遗传调节:从机制到新兴疗法
Rui Gao1,2,3, Meilin Liu1,2,3, Haoyi Yang1,2,3
1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Frontiers in molecular biosciences
|February 17, 2025
概括
表观遗传变化显著影响冠状动脉疾病 (CAD) 的发展,对新疗法至关重要. 了解这些表观遗传机制为改善CAD诊断和干预提供了途径.
科学领域:
- 心血管科学 心血管科学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 动脉样硬化是冠状动脉疾病 (CAD) 的主要原因,是全球主要的死亡原因.
- CAD涉及胆固醇斑块的积累和炎症,狭窄动脉和增加破裂风险.
- 表观遗传学,包括不改变DNA序列的基因表达变化,在CAD病变发生过程中越来越被认可.
研究的目的:
- 审查目前对CAD的表观遗传见解.
- 从表观遗传学的角度探索CAD的病理过程,分子机制和潜在的生物标志物.
- 讨论CAD新兴的表观遗传治疗策略.
主要方法:
- 文献综述综合了最近关于表观遗传学和CAD的发现.
- 专注于关键的表观遗传酶及其向基因.
- 在CAD中分析表观遗传修饰,如DNA甲基化,基因素修饰和非编码RNA.
主要成果:
- 表观遗传变化在CAD发育中发挥着重要作用.
- 表观遗传因素正在从了解疾病机制向治疗应用过渡.
- 关键的表观遗传酶及其向基因被确定为CAD诊断和治疗的关键.
结论:
- 表观遗传洞察力对于推进CAD诊断和干预至关重要.
- 向表观遗传通路为CAD提供了有前途的治疗策略.
- 对关键表观遗传酶和基因的进一步研究可以增强CAD管理.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
Coronary Artery Disease IV: Preventive Measures
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...


